# LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Source: https://onco.cc/trials/nct01828112/  
OnCo record `nct01828112` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ceritinib, Pemetrexed and Docetaxel in Non-small-cell lung cancer, run by Novartis Pharmaceuticals, completed.

## Summary

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib is a phase 3 interventional study registered as NCT01828112 by Novartis Pharmaceuticals, with 231 participants recorded, started 2013-06-28 and reaching its primary completion in 2016-01-26. Interventions recorded: Ceritinib, Pemetrexed, Docetaxel. Conditions recorded: Non-Small Cell Lung Cancer.

Linked to the drug Ceritinib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01828112
- Phase: 3
- Setting: A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 231

## Sources

- ClinicalTrials.gov NCT01828112: https://clinicaltrials.gov/study/NCT01828112

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Ceritinib](https://onco.cc/drugs/ceritinib/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct01828112.json